48,453
edits
(→IHC: +images) |
|||
(3 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
==General== | ==General== | ||
ALK ( | ALK (anaplastic lymphoma (receptor tyrosine) kinase): | ||
*Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal | last1 = Yoshida | first1 = A. | last2 = Tsuta | first2 = K. | last3 = Nakamura | first3 = H. | last4 = Kohno | first4 = T. | last5 = Takahashi | first5 = F. | last6 = Asamura | first6 = H. | last7 = Sekine | first7 = I. | last8 = Fukayama | first8 = M. | last9 = Shibata | first9 = T. | title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. | journal = Am J Surg Pathol | volume = 35 | issue = 8 | pages = 1226-34 | month = Aug | year = 2011 | doi = 10.1097/PAS.0b013e3182233e06 | PMID = 21753699 }}</ref> | *Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal | last1 = Yoshida | first1 = A. | last2 = Tsuta | first2 = K. | last3 = Nakamura | first3 = H. | last4 = Kohno | first4 = T. | last5 = Takahashi | first5 = F. | last6 = Asamura | first6 = H. | last7 = Sekine | first7 = I. | last8 = Fukayama | first8 = M. | last9 = Shibata | first9 = T. | title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. | journal = Am J Surg Pathol | volume = 35 | issue = 8 | pages = 1226-34 | month = Aug | year = 2011 | doi = 10.1097/PAS.0b013e3182233e06 | PMID = 21753699 }}</ref> | ||
**Typically seen in nonsmokers and younger age patients. | **Typically seen in nonsmokers and younger age patients. | ||
**Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal | last1 = Crystal | first1 = AS. | last2 = Shaw | first2 = AT. | title = New targets in advanced NSCLC: EML4-ALK. | journal = Clin Adv Hematol Oncol | volume = 9 | issue = 3 | pages = 207-14 | month = Mar | year = 2011 | doi = | PMID = 21475126 }}</ref> | **Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal | last1 = Crystal | first1 = AS. | last2 = Shaw | first2 = AT. | title = New targets in advanced NSCLC: EML4-ALK. | journal = Clin Adv Hematol Oncol | volume = 9 | issue = 3 | pages = 207-14 | month = Mar | year = 2011 | doi = | PMID = 21475126 }}</ref> | ||
***Resistance to ALK inhibitors may occur due mutations in kinase domain. | ***Resistance to [[ALK inhibitors]] may occur due mutations in kinase domain. | ||
***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Kim | first2 = DW. | last3 = Mehra | first3 = R. | last4 = Tan | first4 = DS. | last5 = Felip | first5 = E. | last6 = Chow | first6 = LQ. | last7 = Camidge | first7 = DR. | last8 = Vansteenkiste | first8 = J. | last9 = Sharma | first9 = S. | title = Ceritinib in ALK-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 370 | issue = 13 | pages = 1189-97 | month = Mar | year = 2014 | doi = 10.1056/NEJMoa1311107 | PMID = 24670165 }}</ref> | ***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Kim | first2 = DW. | last3 = Mehra | first3 = R. | last4 = Tan | first4 = DS. | last5 = Felip | first5 = E. | last6 = Chow | first6 = LQ. | last7 = Camidge | first7 = DR. | last8 = Vansteenkiste | first8 = J. | last9 = Sharma | first9 = S. | title = Ceritinib in ALK-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 370 | issue = 13 | pages = 1189-97 | month = Mar | year = 2014 | doi = 10.1056/NEJMoa1311107 | PMID = 24670165 }}</ref> | ||
*Testing in [[FFPE]] tissue requires ~100 cells.<ref name=pmid25806315>{{Cite journal | last1 = Popper | first1 = HH. | last2 = Tímár | first2 = J. | last3 = Ryska | first3 = A. | last4 = Olszewski | first4 = W. | title = Minimal requirements for the molecular testing of lung cancer. | journal = Transl Lung Cancer Res | volume = 3 | issue = 5 | pages = 301-4 | month = Oct | year = 2014 | doi = 10.3978/j.issn.2218-6751.2014.10.02 | PMID = 25806315 }}</ref> | *Testing in [[FFPE]] tissue requires ~100 cells.<ref name=pmid25806315>{{Cite journal | last1 = Popper | first1 = HH. | last2 = Tímár | first2 = J. | last3 = Ryska | first3 = A. | last4 = Olszewski | first4 = W. | title = Minimal requirements for the molecular testing of lung cancer. | journal = Transl Lung Cancer Res | volume = 3 | issue = 5 | pages = 301-4 | month = Oct | year = 2014 | doi = 10.3978/j.issn.2218-6751.2014.10.02 | PMID = 25806315 }}</ref> | ||
Line 24: | Line 24: | ||
===Images=== | ===Images=== | ||
<gallery> | <gallery> | ||
Image: ALK positive lung adenocarcinoma -- very low mag.jpg | ALK +ve lung adenoca - very low mag. | Image: ALK positive lung adenocarcinoma -- very low mag.jpg | ALK +ve lung adenoca - very low mag. (WC) | ||
Image: ALK positive lung adenocarcinoma -- low mag.jpg | ALK +ve lung adenoca - low mag. | Image: ALK positive lung adenocarcinoma -- low mag.jpg | ALK +ve lung adenoca - low mag. (WC) | ||
Image: ALK positive lung adenocarcinoma -- intermed mag.jpg | ALK +ve lung adenoca - intermed. mag. | Image: ALK positive lung adenocarcinoma -- intermed mag.jpg | ALK +ve lung adenoca - intermed. mag. (WC) | ||
Image: ALK positive lung adenocarcinoma -- high mag.jpg | ALK +ve lung adenoca - high mag. | Image: ALK positive lung adenocarcinoma -- high mag.jpg | ALK +ve lung adenoca - high mag. (WC) | ||
Image: ALK positive lung adenocarcinoma -- very high mag.jpg | ALK +ve lung adenoca - very high mag. | Image: ALK positive lung adenocarcinoma -- very high mag.jpg | ALK +ve lung adenoca - very high mag. (WC) | ||
</gallery> | </gallery> | ||
====www==== | ====www==== | ||
Line 61: | Line 61: | ||
*[[Lung tumours]]. | *[[Lung tumours]]. | ||
*[[Lung carcinoma with EGFR mutation]]. | *[[Lung carcinoma with EGFR mutation]]. | ||
*[[ALK translocation renal cell carcinoma]]. | |||
==References== | ==References== |
edits